Living Immunotherapies

Pioneering TCR-T Immunotherapies for Cancer Patients

About Medigene

Medigene is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering.

Medigene’s End-to-End Platform

The basis of Medigene’s differentiation is our End-to-End Platform of multiple, combinable, exclusive and proprietary technologies. These technologies have the potential to enhance our TCR-T drug products from a safety, durability and efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.

Target
Screening

TCR
Generation & optimization

TCR-T Therapy armoring & enhancement

Manufacturing tCR-T Drug products

Clinical Development

MDG1015: BRINGING OUR TCR THERAPIES TO PATIENTS

3rd generation NY-ESO-1 targeted TCR-T therapy combined with our PD1-41BB switch protein- a sensitive, specific TCR with a favorable safety profile

Immunotherapy Pipeline

Our End-to-End Platform allows to develop highly innovative, complementary treatment options for various cancer types

 

Our TCR Technology

Our End-to-End Platform enables us to generate TCR-T cells with high sensitivity, specificity and safety

Our Partners

We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.